Close Menu

NEW YORK (GenomeWeb) – Goldman Sachs today upgraded shares of Alere to a Buy rating, but downgraded Quest Diagnostics' shares to Neutral. 

In a research note, analyst Isaac Ro upgraded Alere from a previous Neutral rating and said that he believes that Alere's new management has brought focus to the firm's new products, streamlined its cost structure, and reduced its debt. As a result, he anticipates revenues to grow about 6 percent between the firm's fiscal years 2015 and 2018, and EPS to grow 17 percent during the same period. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.